Our results indicate the existence of miRNA expression patterns that could distinguish between sensitive and resistant NSCLC patients with EGFR activating exon 19 deletion mutations, therefore identifying those who could benefit from EGFR-TKIs and providing promising therapeutic opportunities. This evidence concerns the gene EGFR and non-small cell lung carcinoma.